Allegra Orthopaedics company announcements 202431/10/2024: AGM Extension Announcement15/10/2024: Notice of Compulsory Acquisition10/10/2024: Shareholders Update09/10/2024: Supplementary Bidder's Statement07/10/2024: Change in Substantial Holding04/10/2024: Initial Director’s Interest Notice04/10/2024: Final Director's Interest Notice03/10/2024: Changes to Allegra Directors and Non-Executive Chairman03/10/2024: Change in Substantial Holding30/09/2024: Variation of Takeover Bid17/09/2024: Change in Substantial Holding16/09/2024: Variation of Takeover Bid12/09/2024: Changes To Securities - Additional and Buy Backs11/09/2024: Notification of Cessation of Securities03/09/2024: Shareholders Update02/09/2024: Variation of Takeover Bid30/08/2024: Shareholders Update30/08/2024: Change of Director's Interest Notice30/08/2024: Change of Director's Interest Notice14/08/2024: Change in Substantial Holding13/08/2024: Change in Substantial Holding12/08/2024: Shareholders Update09/08/2024: Notice of Status of Conditions09/08/2024: Supplementary Bidder's Statement30/07/2024: Change in Substantial Holding29/07/2024: Shareholder Update24/07/2024: Takeover - Extension Of Offer Period22/07/2024: Change in Substantial Holding19/07/2024: Change in Substantial Holding19/07/2024: First Supplementary Target's Statement19/07/2024: Change in Substantial Holding17/07/2024: Change in Substantial Holding11/07/2024: Change in Substantial Holding10/07/2024: Extension of Offer Period10/07/2024: Notice of Condition Fulfilled04/07/2024: Lodgement of Target’s Statement02/07/2024: Change of Company Secretary01/07/2024: Supplementary Bidder's Statement01/07/2024: Notice of Change in Substantial Holding26/06/2024: Change in substantial holding21/06/2024: Change in Substantial Holding21/06/2024: Supplementary Bidder's Statement20/06/2024: Despatch of Bidder's Statement19/06/2024: Change in Substantial Holding19/06/2024: Bidder's Statement17/06/2024: Notice of Register Date27/05/2024: Company Announcement - Recommended Cash Takeover Offer22/03/2024: Continuation of Suspension from Quotation22/03/2024: Suspension and Half Year Financials Update22/03/2024: Appendix 4D and Half Year Financial Report08/03/2024: Suspension and Half Year Financials Update25/02/2024: Allegra Medical Technologies Limited (ASX AMT) – Request for Voluntary Suspension23/02/2024: Suspension from Official Quotation21/02/2024: Confirmation of Release - AMT - Trading Halt06/02/2024: Spinal Cage FDA Submission Update202308/12/2023: Notification of Cessation of Securities05/12/2023: Spinal Cage FDA Submission Update10/11/2023: Change of Director’s Interest Notice10/11/2023: Notification of Cessation of Securities10/11/2023: Change of Director’s Interest Notice02/11/2023: Change of Company Name31/10/2023: Results of 2023 Annual General Meeting20/10/2023: Unlisted Options Expiring12/10/2023: Confirmation of Compliance with ASX Chapter 1229/09/2023: 2023 AGM - Notice of Meeting, Letter of Access and Proxy28/09/2023: Spinal Cage FDA Submission Timeline Update06/09/2023: Change of Director’s Interest Notice06/09/2023: Notice of Change of Interests of Substantial Holder06/09/2023: Change of Director’s Interest Notice06/09/2023: Spinal Cage FDA Submission Update – Supplementary Announcement03/09/2023: Appendix 4G and Corporate Governance Statement03/09/2023: Appendix 4E and Annual Report30/08/2023: Results of Pro-Rata Non-Renounceable Entitlement Offer28/08/2023: Completion of Sale of the Orthopaedic Division26/08/2023: Results of 2023 General Meeting16/08/2023: Spinal Cage FDA Submission Update25/07/2023: EGM Notice of Meeting and Proxy25/07/2023: 2023 General Meeting Letter of Access and Proxy19/07/2023: Proposed issue of securities19/07/2023: Notice under section 708AA(2)(f) of the Corporations Act 2001 (Cth)19/07/2023: Letter to Option Holder19/07/2023: Letter to Ineligible Shareholders19/07/2023: Pro Rata Non-Renounceable Entitlement Offer Booklet19/07/2023: Rights Issue & Update on Sale of Orthopaedic Asset27/06/2023: Extension of Loan Agreement with RIPL02/05/2023: Company Update on Sale of Orthopaedic Asset31/03/2023: AMT Submits 510(k) for Spinal Cage FDA Clearance22/02/2023: Sr-HT-Gahnite Large Animal Study Results03/02/2023: Company Update Correction202231/10/2022: 2022 AGM Letter to Shareholders and Proxy Form11/08/2022: Company Update05/08/2022: Sr-HT-Gahnite Biological Testing11/07/2022: AMT Securities Cessation Notification14/03/2022: Sr-HT-Gahnite Systemic Safety Milestone25/02/2022: Appendix 4D and Half Year Financial Report08/02/2022: Resignation of Company Director04/02/2022: Change in Company Secretary31/01/2022: Sr-HT-Gahnite Large Animal Study Shows Positive Results202109/08/2021: Improving Coating Techniques for Orthopaedic Implants26/07/2021: Change of Share Registry19/04/2021: Management Change - New Head of Technology and Innovation06/04/2021: Sr-HT-Gahnite - Successful Pilot Animal Study07/03/2021: Half Year Report202021/12/2020: Sr-HT-Gahnite - further positive results09/12/2020: Sr-HT-Gahnite Project Announcement25/09/2020: Annual Report 30 June 202030/08/2020: Appendix 4E and Full Year Accounts07/08/2020: Sr-HT-Gahnite update08/07/2020: Acquisition of Patents Additional Information08/07/2020: Section 708A Notification08/07/2020: Appendix 2A07/07/2020: Patent Acquisition for Unique Synthetic Bone Substitute02/06/2020: Product Revenue - June 202012/05/2020: Face Shield Announcement27/03/2020: Covid-19 Announcement201918/11/2019: Announcement30/09/2019: Security Holder Information30/09/2019: Notice of 2019 AGM30/09/2019: Appendix 4G & Corporate Governance Statement30/08/2019: Appendix 4E & Full Year Accounts21/02/2019: Appendix 4D & Half Year Report201821/11/2018: Bone Substitute Project - FDA Announcement08/10/2018: Annual Report - 30 June 201829/08/2018: Appendix 4E Financial Report 30 June 201806/08/2018: IMCRC Grant Announcement18/04/2018: MTPConnect Grant Announcement07/03/2018: Non-executive Director Announcement22/02/2018: Half Year Financial Report – 31122017201714/12/2017: Waldemar LINK GmbH & Co Distribution Agreement30/08/2017: Annual Report – 30 June 201730/08/2017: Appendix 4G – Corporate Governance29/08/2017: Appendix 4E Annual Report – 30 June 201725/08/2017: Bone Substitute Project Update17/08/2017: Kangaroo Tendon Collaboration Announcement10/02/2017: Bone Substitute Project Update19/01/2017: Company Secretary Resignation / Appointment201616/12/2016: Cleansing Statement12/12/2016: Appendix 3B New Issue Announcement30/11/2016: Results of AGM30/11/2016: Corporate Update for AGM23/11/2016: Appointment of Auditor31/10/2016: Media Release – Bone Substitute Project Business Update26/10/2016: Notice of Annual General Meeting26/10/2016: Annual General Meeting – Proxy Form26/10/2016: Independent Expert’s Report20/09/2016: Appendix 3B New Issue Announcement20/09/2016: Media Release – Bone Substitute Project Update30/08/2016: Annual Report – 30 June 201630/08/2016: Appendix 4E Annual Report – 30 June 201630/08/2016: Appendix-4G Corporate Governance30/08/2016: Management Change30/08/2016: Corporate Governance Statement30/08/2016: Appendix 4G – Corporate Governance17/08/2016: Kangaroo Tendon Collaboration Announcement05/07/2016: 30/06/2016: Bone Substitute Project Loan07/06/2016: Bone Substitute Project Update20/04/2016: Update on Management Changes05/02/2016: Update on outsourcing of Manufacturing201518/11/2015: Appointment of Director18/11/2015: Initial Director’s Interest Notice04/11/2015: Media Release – Outsource of Manufacturing02/11/2015: Final Director’s Interest Notice29/10/2015: Change of Management Notice28/10/2015: Annual General Meeting results 201529/09/2015: Change of Management Notice28/09/2015: Appendix 4E Preliminary Annual Report 30 June 201525/09/2015: Annual General Meeting – Proxy Form25/09/2015: Notice of Annual General Meeting25/09/2015: Annual Report – 30 June 201517/03/2015: Cancellation of Shares201425/12/2014: Half Year Report to 31 December 201427/11/2014: Change of Company Name26/11/2014: Results of AGM 201426/11/2014: Final Director’s Interest Notice26/11/2014: Initial Director’s Interest Notice26/11/2014: Director Appointment/Resignation20/11/2014: Change In Substantial Shareholding Notice19/11/2014: Change in Substantial Shareholding Notice19/11/2014: Becoming a substantial holder31/10/2014: Awarded $1.6M by the NSW Medical Devices Fund30/10/2014: Trading Halt Request30/10/2014: Trading Halt28/10/2014: Appendix 3B28/10/2014: Appendix 3B24/10/2014: Close of Rights Issue Offer24/10/2014: Notice of Annual General Meeting/Proxy Form10/10/2014: Right Issue – Entitlement and Acceptance Form10/10/2014: Rights Issue – Despatch of Documents to Eligible Shareholders02/10/2014: Replacement Rights Prospectus01/10/2014: Rights Issue – Notice to Ineligible Shareholders01/10/2014: Rights Issue – Notice to Eligible Shareholders29/09/2014: Non-Renounceable Pro Rata Rights Issue29/09/2014: Rights Issue Prospectus29/09/2014: Annual Report – 30 June 201429/09/2014: Annual Report – 30 June 201422/09/2014: Media Release Small Bone Innovations29/08/2014: Appendix 4E Preliminary Final Report 30 June 201402/04/2014: Synthetic Bone Substitute Licence from The University of Sydney28/02/2014: Half Yearly Report and Accounts21/02/2014: Expiry of Options201330/10/2013: Results of 2013 Annual General Meeting27/09/2013: Notice of Annual General Meeting/Proxy Form18/09/2013: Annual Report – 30 June 201330/08/2013: Appendix 4E Preliminary Final Report/Annual Report – 30 June 201309/08/2013: Cancellation of Options07/08/2013: ASX Media Release – Signs Transitional Services Agreement with Orthofix01/05/2013: Appoints New Chief Executive Officer04/04/2013: Non-Renounceable Rights Issue – Notice of Under Subscriptions11/03/2013: Notice to Ineligible Shareholders – Rights Issue11/03/2013: Notice of Despatch – Rights Issue26/02/2013: Rights Issue Notice to Shareholders26/02/2013: Rights Issue Notice to Optionholders25/02/2013: Rights Issue – Revised Timetable25/02/2013: Rights Issue – Offer Document – Revised Timetable25/02/2013: Entitlement Acceptance Form – Revised Timetable25/02/2013: Appendix 3B-Revised Rights Timetable25/02/2013: Cleansing Statement-Rights Issue – Revised Timetable22/02/2013: Cleansing Statement – Rights Issue22/02/2013: Rights Issue – Entitlement and Acceptance Form22/02/2013: Placement Cleansing Statement22/02/2013: Half Yearly Reports and Accounts22/02/2013: Non-Renounceable Pro Rata Rights Issue to raise $1.5m22/02/2013: Appendix 3B – Rights Issue22/02/2013: Rights Issue Offer Document20/02/2013: Substantial Shareholder Notice Form 60319/02/2013: Placement & Rights Issue19/02/2013: New Issue Announcement201214/12/2012: ASDM 2012 Shareholder Update29/11/2012: Results of 2012 Annual General Meeting23/10/2012: Appendix 3B New Issue Announcement28/09/2012: Annual Report – 30 June 201231/08/2012: Preliminary Final Results30/07/2012: Video – Achieving medical breakthroughs matters to Hala Zreiqat17/07/2012: ASX Market Announcements26/03/2012: Executive Management Changes27/02/2012: ASDM – Interim Report16/02/2012: ASDM Expands Product Portfolio201123/11/2011: Appoints Director23/11/2011: Initial Director’s Interest Notice25/10/2011: Results of Annual General Meeting25/10/2011: Chairman’s Address to Shareholders25/10/2011: CEO’s AGM Address26/09/2011: Annual Report 201123/09/2011: Notice of Annual General Meeting and Shareholder Voting Form20/09/2011: ASDM Enters The $250M Australian Spinal Market With Global Brand31/08/2011: Appendix 4E Preliminary Final Report31/08/2011: 2011 Full Year Results16/05/2011: Shareholder Newsletter – May 201104/03/2011: Signs Commercial Arrangement with Surgeon Group02/03/2011: Interim Report – 31 December 201002/03/2011: Results for the half year ended 31 December 201016/02/2011: Completes Strategic Review14/02/2011: Appoints National Sales Manager201006/12/2010: Positive Interim Results For Clinical Trial15/11/2010: Amended Constitution15/11/2010: Appendix 3Z Final Director’s Interest Notice05/11/2010: 2010 AGM – Chairman’s Address05/11/2010: 2010 AGM – CEO Presentation04/11/2010: New Distribution Agreement Broadens Market20/10/2010: New Distribution Agreement For Substantial Growth In Sales And Profit11/10/2010: Signs Distribution Agreement With Arthrosurface Inc07/10/2010: Appendix 3Y Change of Director’s Interest Notice01/10/2010: 2010 Proxy Form01/10/2010: 2010 AGM Notice27/09/2010: Annual Report 201020/09/2010: Major New Revenue Opportunities15/09/2010: Appendix 3X Initial Director’s Interest Notice31/08/2010: Appendix 4E Preliminary Final Report06/07/2010: ASDM Signs Landmark PAD Licensing Deal08/06/2010: Broadcast – First PAD trial patient discharged08/06/2010: Shareholders Newsletter June 201019/05/2010: Establishes direct presence in Europe09/04/2010: ASX Media Release – Major Trial For World-First Major Limb Saving26/03/2010: Appendix 3B New Issue Announcement22/03/2010: Presentation of PAD Pilot Trial Results at Association of International Vascular Surgeons Conference01/03/2010: Appendix 3Y Change of Director’s Interest Notice01/03/2010: Appendix 3X Initial Director’s Interest Notice01/03/2010: Appointment of Director01/03/2010: FDA Registration Posterior Stabilised Knee22/02/2010: Half year press release22/02/2010: Appendix 4D200907/12/2009: New Issue Announcement Appendix 3B02/12/2009: First Sales in Continental Europe Class III CE Mark26/11/2009: 2009 AGM Chairmans Report26/11/2009: 2009 AGM CEO Report26/11/2009: 2009 AGM Results of Meeting29/10/2009: Surgical Device sold to US multi-national29/09/2009: Annual Report 200901/09/2009: Cancellation of Options26/08/2009: 2009 Full Year Results26/08/2009: Appendix 4E Preliminary Final Report21/07/2009: Newsletter26/06/2009: US Distributor Announcement200820/11/2008: Change of Director’s Interest Notice20/11/2008: Appendix 3B12/11/2008: Results of Meeting12/11/2008: Chairman’s Address to Shareholders29/10/2008: Business Update10/10/2008: Proxy Form10/10/2008: Notice of Annual General Meeting09/10/2008: Change of Director’s Interest Notice01/10/2008: Shareholder Business Update30/09/2008: Annual Report 200803/09/2008: Change of Director’s Interest Notice28/08/2008: Change of Director’s Interest Notice20/08/2008: Appendix 4E Preliminary Final Report20/08/2008: 2008 Full Year Results28/07/2008: PLD Portland Denies Hip Cup Patent Infringement24/07/2008: US Hip Cup Patent21/07/2008: Investor update21/05/2008: US Patent on Pivotal Hip Prosthesis Design21/04/2008: April 08 Investor Update03/04/2008: PAD on ABC’s Catalyst Program06/03/2008: Licensing of Polishing Technology26/02/2008: Feb 08 CEO Roadshow Presentation22/02/2008: ASX Announcement December 2007 Half Year Results22/02/2008: December 2007 Half Year Results31/01/2008: 10th Patient Treated with PAD200721/12/2007: Results of 2007 AGM20/12/2007: Chairman & CEO AGM Addresses14/12/2007: Notice of Initial Substantial Holder11/12/2007: Notice of Initial Substantial Holder11/12/2007: MD presentation at Informa National Prostheses Congress Syd07/12/2007: Change of Director`s Interest Notice07/12/2007: Initial Director`s Interest Notice06/12/2007: AMT Lists on ASX – Interview with MD Dr Greg Roger06/12/2007: AGM Proxy Form06/12/2007: Notce of Annual General Meeting30/11/2007: Confirmation of Employee Share Issue30/11/2007: Voluntary Escrow30/11/2007: Distribution Schedule30/11/2007: ASX Circular: Commencement of Official Quotation30/11/2007: 2006 Annual Report30/11/2007: Corporate Governance Statement30/11/2007: Employee Option Terms30/11/2007: Admission to Official List30/11/2007: Top 20 Shareholders30/11/2007: Constitution30/11/2007: Appendix 1A: ASX Listing Application and Agreement30/11/2007: 2005 Annual Report30/11/2007: Pro Forma Balance Sheet30/11/2007: Escrowed Securities30/11/2007: Option Terms30/11/2007: Pre Quotation Disclosure30/11/2007: 2007 Annual Report30/11/2007: Employee Share Option Plan14/11/2007: Prospectus
